SARI (Serotonin Antagonist and Reuptake Inhibitor)
Pregnancy: Avoid if possible — limited data. Use sertraline in preference.
Trazodone
Brand names: Molipaxin
Adult dose
Dose: Depression with anxiety or insomnia: 150mg OD at night initially (or 50mg TDS); increase by 50mg every 3–4 days; usual effective dose 150–300mg OD. Maximum 600mg daily (hospitalised patients under specialist care).
Route: Oral
Frequency: Once daily at night (preferred) or divided doses
Max: 600mg daily (inpatient specialist setting); 300mg OD (outpatients)
Mechanism: 5-HT2A receptor antagonist AND serotonin reuptake inhibitor. Useful when sedation is a therapeutic goal (insomnia with depression). Lower anticholinergic burden than TCAs. Associated with priapism (rare but serious — urological emergency). Often used at sub-antidepressant doses (50–100mg ON) specifically as a non-addictive sleep aid in depression.
Paediatric dose
Route: Oral
Frequency: Once daily at night
Max: Not applicable
Not licensed under 18 years. Seek specialist child and adolescent psychiatry opinion.
Dose adjustments
Renal
Use with caution in severe renal impairment — limited data.
Hepatic
Reduce dose in hepatic impairment — hepatic metabolism.
Clinical pearls
- Priapism: advise male patients at initiation — rare (1:6000) but can cause permanent erectile dysfunction if not treated promptly (aspiration, alpha-agonist injection). Advise patient to attend ED immediately for erection lasting >4 hours
- Sub-antidepressant use for insomnia: 50–100mg ON is widely used as a non-addictive sleep aid — not a scheduled/controlled drug unlike zopiclone or benzodiazepines
- Orthostatic hypotension: particularly problematic in the elderly — check standing BP; start low (50mg)
- No anticholinergic activity — safer in elderly than TCAs, BPH patients
Contraindications
- MAOIs within 14 days
- Hypersensitivity to trazodone
- Acute intoxication with alcohol or CNS depressants
Side effects
- Sedation (therapeutically useful)
- Orthostatic hypotension (alpha-1 blockade)
- Dizziness, headache
- Nausea
- Dry mouth (minimal anticholinergic effect)
- Priapism (rare but urological emergency — advise patient to seek emergency care immediately)
- QTc prolongation (at higher doses)
Interactions
- MAOIs — contraindicated (serotonin syndrome)
- CNS depressants, alcohol — additive sedation
- CYP3A4 inhibitors (ketoconazole, ritonavir) — increase trazodone levels; reduce dose
- Digoxin, phenytoin — trazodone may increase levels
Monitoring
- Blood pressure (orthostatic — sit to stand)
- Mood and sleep response
- Priapism awareness counselling (men)
Reference: BNFc; BNF 90; NICE CG90 (Depression). Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF